We advice our patients to give the following letter, listing all the drugs on this website, to all of their health care professionals (including their general practitioner, dentist and pharmacist). Although the most appropriate treatment of Brugada syndrome is under discussion, avoidance of potentially proarrhythmic drugs and treatment of fever (which is a well-known trigger of cardiac events in Brugada syndrome) are generally accepted to be an important part of (prophylactic) treatment. However, some patients may (only) be appropriately treated with an implantable cardioverter-defibrillator. Some drugs may have an antiarrhythmic effect and may be used favorably in the acute or chronic setting (see potential antiarrhythmic drugs).
Please know that, as every patient is unique, not all these drugs will be harmful for every Brugada syndrome patient, and that some drugs may be beneficial for other reasons. We advice caution and close monitoring when any of these drugs are administered. For detailed information on the drugs we refer to the Avoid and Preferably Avoid pages.
This patient letter has been translated into several languages by our colleagues. When you would appreciate to receive an email when the content of the letter is changed importantly (i.e. drugs added, removed or with changed qualification), please send us your update request here.
The last update of this patient letter has been in September 2013, since then there have been no important changes to the avoid and preferably avoid lists. Please know that we are constantly evaluating the medical literature for new and critical data regarding drug safety in Brugada syndrome. On the front page (here) you can find when we last updated the website.
When your own language is currently not available, you may want to use the Google translation tool for this letter. You can find it here.
Click below on the language of your choice to download your patient letter.
|Catalan||Prof. J. Brugada, MD, PhD||October 2013|
|Chinese||Prof. H.Y. Wu, MD, PhD||October 2013|
|Dutch||P.G. Postema, MD, PhD||October 2013|
|English||P.G. Postema, MD, PhD||October 2013|
|French||Prof. V. Probst, MD, PhD||October 2013|
|German||C. Veltmann, MD||October 2013|
|Hebrew||Prof. S. Viskin, MD||October 2013|
|Italian||Prof. S.G. Priori, MD, PhD||October 2013|
|Japanese||Prof. M. Hiraoka, MD, PhD /
Y. Mizusawa, MD
|Norwegian||Prof. K. Gjesdal, MD, PhD||October 2013|
|Portuguese||Prof. A.R. Perez Riera, MD, PhD||October 2013|
|Spanish||Prof. J. Brugada, MD, PhD||October 2013|
|Swedish||Prof. L. Bergfeldt, MD, PhD||October 2013|
|Thai||Prof. K. Nademanee, MD, PhD /
Dr. G. Veerakul